Interview Synopsis

Tigermed & China's clincial CROs

  • Public Equity
  • Healthcare
  • Greater China

Following the recent first-quarter net profit increase for Tiger Pharmaceuticals, Third Bridge held an Interview with a former business development manager at Hangzhou Tigermed Consulting. It covered the pricing mechanism and dynamics of contract research organisations (CROs), as well as its business model and the company’s sub-segments.

A Look at China’s Rapidly Growing CRO Market

The former business development manager at Hangzhou Tigermed Consulting discussed the clinical CRO market in China, voicing the opinion that the market is still in its infancy and it would continue to grow at a rapid rate. However, there could be hurdles for the company in the future, which the specialist outlined extensively in the Interview.

The specialist also explained the different services provided by Tigermed and its subsidiaries, taking clients through the revenue shares for the different categories. Despite his positive outlook on the company, he noted which areas of the business were underperforming.

The specialist explained the pricing structure and strategies for clinical research projects and how they could change in the future. He spoke about innovations in government policies, including the impact that the “4+7” centralised procurement policy (which we covered in Q1’s Healthcare Trend Report) would have on the rate of approval for generic drugs.

To access all the human insights from Third Bridge’s Tigermed Interview, click below to view the full transcript.

Related Transcripts

The information used in compiling this document has been obtained by Third Bridge from experts participating in Forum Interviews. Third Bridge does not warrant the accuracy of the information and has not independently verified it. It should not be regarded as a trade recommendation or form the basis of any investment decision.

For any enquiries, please contact